Ubiquigent, a drug discovery firm specialising in ubiquitin cell-signalling, has received £500k ($800k) investment from commercialisation firm the IP Group and government agency Scottish Enterprise (SE), via SE’s investment arm the Scottish Investment Bank.
The firm, which is a spin-out of the University of Dundee and still located on campus, will use the latest round of funding to accelerate development and commercialisation of its drug discovery platforms.
Ubiquigent also announced that Dr Mark Tregerne, a pharmaceutical industry veteran with 25 years of experience, will join the company’s board of directors as a non-executive director.
Treherne said: “I look forward to working closely with the Ubiquigent team to support the company in the planning and execution of its strategy in this high growth potential field.”
